

Latvia

Population (January 2013):	2 023 825
Human development Index (2013):	LV: 0.810
HAV vaccine recommendations:	HAV vaccination is not included in the national childhood immunization programme. Vaccination is recommended for: 1. travellers to endemic areas 2. people infected with HBV or HCV 3. For outbreak control.
Seroprevalence studies by quality score:	score 0: 0 studies score 1: 0 studies score 2: 0 studies
Seroprevalence studies timeframe:	-

Seroprevalence assessment: **no data available**
 Incidence assessment: **intermediate**
 Susceptibility in adults: **no data available**


No study on HAV seroprevalence could be found on Latvian population.

Latvia_Table 1. Hepatitis A seroprevalence level by time period

	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

Available incidence data from 1990 shows a steady decrease from more than 250 cases per 100 000 to 5 cases per 100 000 in 2001. Reported incidence in TESSy from 2006 to 2012 widely oscillates from less than 1 case per 100 000 in 2007 and 2012 to more than 100 cases per 100 000 in 2008 and 2009 (Latvia_Figure 2).

Latvia_Figure 1. Reported incidence of hepatitis A in Latvia, 1990-2013



National data source: personal communication from ECDC National Focal Point/Operational Contact Point, Centre for Disease Prevention and Control of Latvia

Bibliography

1. Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, et al. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: Review and consensus statement on hepatitis A and B vaccination. J Travel Med. 2007;14(3):181-7.